-+ 0.00%
-+ 0.00%
-+ 0.00%

Agenus To Highlight New Data At AACR-IO Exploring Systemic And Tumor Inflammation Biomarkers With BOT/BAL In Immunologically Cold Tumors

Benzinga·02/09/2026 18:04:12
Listen to the news

Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that new translational and clinical biomarker analyses from its botensilimab (BOT) immunotherapy program have been accepted for poster presentation at the American Association for Cancer Research- Immuno-Oncology (AACR-IO) Conference, taking place in Los Angeles, CA on February 18–21, 2026.

The abstract, titled "Systemic and tumor-microenvironment inflammation shape outcomes in patients with immunologically cold, treatment-refractory tumors treated with Fc-enhanced anti–CTLA-4 botensilimab," evaluates how systemic inflammatory markers, tumor microenvironment (TME) immune activity, and peripheral immune cell states are associated with clinical outcomes in patients treated with BOT alone or in combination with balstilimab (BAL).

Botensilimab is an Fc-enhanced multifunctional anti-CTLA-4 antibody designed to help prime and activate the immune system, while BAL is an anti-PD-1 antibody designed to help sustain immune activity against cancer. Together, BOT+BAL targets complementary immune pathways and is being evaluated across multiple solid tumors, including immunologically "cold" or treatment-refractory cancers.